Retatrutide – Mechanism, Trials & Uses
Retatrutide is an investigational drug for obesity and type 2 diabetes that simultaneously activates three hormone receptors to reduce body weight and improve blood sugar control.
Things worth knowing about "Retatrutide"
Retatrutide is an investigational drug for obesity and type 2 diabetes that simultaneously activates three hormone receptors to reduce body weight and improve blood sugar control.
What is Retatrutide?
Retatrutide is an innovative investigational drug belonging to the class of so-called triple agonists. It is currently being evaluated in clinical trials for the treatment of obesity and type 2 diabetes mellitus. Unlike already approved medications such as semaglutide or tirzepatide, retatrutide simultaneously targets three distinct hormone receptors, giving it a uniquely broad pharmacological profile.
Mechanism of Action
Retatrutide works by simultaneously activating three hormone receptors:
- GLP-1 receptor (Glucagon-like Peptide-1): Stimulates insulin secretion, suppresses glucagon release, and slows gastric emptying, leading to increased satiety and reduced food intake.
- GIP receptor (Glucose-dependent Insulinotropic Polypeptide): Enhances insulin secretion in response to meals and positively influences fat metabolism.
- Glucagon receptor: Increases energy expenditure and promotes the breakdown of fat tissue (lipolysis), further supporting weight loss.
Through this triple mechanism, retatrutide can regulate blood glucose levels, achieve significant reductions in body weight, and improve overall metabolic function.
Indications
Retatrutide is still in clinical development and is not yet approved for general use. The primary areas under investigation include:
- Obesity: Weight reduction in adults with a BMI of 30 or above, or overweight with obesity-related comorbidities.
- Type 2 diabetes mellitus: Improvement of glycaemic control in patients with inadequately managed diabetes.
- Non-alcoholic fatty liver disease (NAFLD/NASH): Potential beneficial effects on liver conditions associated with metabolic dysfunction.
Clinical Trials and Efficacy
In a Phase 2 trial (TRIUMPH-1, published in 2023), retatrutide demonstrated remarkable results:
- Patients with obesity lost an average of up to 24% of their body weight over 48 weeks – the highest figure reported for any drug in this class at the time.
- Significant improvements in HbA1c levels (long-term blood glucose marker) were observed in patients with type 2 diabetes.
- Positive effects on blood lipids, blood pressure, and other cardiometabolic risk factors were also noted.
Phase 3 trials to confirm these findings are planned or already underway.
Dosage and Administration
In clinical studies, retatrutide was administered as a subcutaneous injection (under the skin) once weekly. Doses were gradually increased (titrated) to improve tolerability. The exact approved dosage has not yet been established, as the drug has not received regulatory approval.
Side Effects
As with other incretin-based medications, the most common side effects of retatrutide are gastrointestinal in nature:
- Nausea and vomiting
- Diarrhoea or constipation
- Decreased appetite
- Abdominal pain or discomfort
These side effects are typically most pronounced at the beginning of treatment and tend to diminish over time. Serious adverse events such as pancreatitis (inflammation of the pancreas) or gallbladder-related issues are possible and have been observed in studies. Medical supervision is therefore essential.
Comparison with Other Agents
Compared to approved medications from a similar class, retatrutide can be positioned as follows:
- Semaglutide (GLP-1 agonist): Acts on a single receptor; achieves approximately 15% body weight reduction.
- Tirzepatide (GLP-1/GIP dual agonist): Acts on two receptors; achieves approximately 20% body weight reduction.
- Retatrutide (triple agonist): Acts on three receptors; has achieved up to 24% body weight reduction in studies.
Important Notes
As retatrutide has not yet received regulatory approval, it is not commercially available and may only be used within the framework of authorised clinical trials. Patients interested in participating in such trials should consult their treating physician or contact specialised trial centres. The use of unapproved substances or products obtained through unofficial channels is strongly discouraged.
References
- Jastreboff AM et al. – Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People with Obesity. New England Journal of Medicine, 2023. DOI: 10.1056/NEJMoa2301972
- Eli Lilly and Company – Retatrutide (LY3437943) Clinical Development Program, study registration at ClinicalTrials.gov (NCT04881760).
- Holst JJ & Rosenkilde MM – GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Physics. The Journal of Clinical Endocrinology & Metabolism, 2020.
Most purchased products
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®The latest entries
3 Posts in this encyclopedia categoryPancreatic enzyme kinetics
Dermatoscopy
Most read entries
3 Posts in this encyclopedia categoryMagnesiumcarbonat
Calorie content
Cologne list
Related search terms: Retatrutide